⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BLRX News
BioLineRX Ltd
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
prnewswire.com
BLRX
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
prnewswire.com
BLRX
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
prnewswire.com
BLRX
BLRX